top of page

How Cambridge Innovation Capital has become a preeminent investment firm in Cambridge life sciences, and also a significant attractor of outside capital to Cambridge

  • blonca9
  • May 5, 2024
  • 1 min read

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for those who are interested in investing in Cambridge innovation.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page